FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-60
SponsorNational Institute of Environmental Health Sciences (NIEHS)

About this trial

Dermatomyositis (DM) is a rare autoimmune disease that causes muscle weakness, skin rashes, and other symptoms. Researchers think both genetic and environmental factors play a role in this disease. They want to find out more about how diet and lifestyle choices affect people with DM/JDM.

Objective:

To see if omega-3 fatty acid supplements from fish oil, combined with a healthy diet, can help people with DM/JDM.

Eligibility:

Adults 18-60 years old, who live in the United States, can read English, and access Internet to complete questionnaires can participate.

Design:

Participants will have 5 or 6 inpatient visits. For 5 visits they may need to stay in the Clinical Center for up to 5 days. Participants will be screened. They will have a physical exam with blood, urine and stool tests. They will have tests of their heart and lung function. Their muscle strength will be measured. They may have an imaging scan of their thighs and pelvis. They will complete online questionnaires about their health and lifestyle. They may complete two optional skin biopsies. Participants will take 4 small capsules by mouth twice a day for up to 6 months. The capsules will contain omega-3 fatty acids from fish oil or a placebo. The placebo looks just like the regular capsule but contains no active ingredients. Participants will not know which capsules they are taking. They will follow a healthy diet based on the General Healthy Eating Pattern.

Participants will receive dietary coaching and will have virtual check-ins throughout the study. For two 7-day periods, they will wear a watch-like device to track their daily activity and sleep patterns. Participants may opt to remain in the study for an additional 12 weeks. All will receive the fish oil supplements during this stage.

Eligibility criteria

Qualifiers

Adults 18-60 years of age with probable or definite EULAR-ACR criteria for adult or juvenile dermatomyositis (DM, JDM).

Willingness to adhere to the general healthy diet pattern regimen, undergo dietary coaching on weekly to biweekly basis (10 sessions), and to complete online random reporting of dietary intake over a 6-month period.

Ability and willingness to comply with taking 4 study pills twice a day for 6 months.

Ability and willingness to wear ActiGraph device at home for 7 continuous days, twice in the study.

Disqualifiers

Polymyositis; inclusion body myositis; cancer-associated myositis, defined as the diagnosis of myositis within 3 years of the diagnosis of cancer, except basal or squamous cell skin cancer or carcinoma in situ of the cervix if at least 5 years since excision.

Drug- or toxin-induced myositis, including known HMG-CoA reductase autoantibody-positive necrotizing myopathy following statin use.

Moderate to severely active myositis that would require initiation of another immunosuppressive treatment.

Joint disease, severe calcinosis, or other musculoskeletal condition, which precludes the ability to assess/quantitate muscle strength and function.

Trial design

Treatments tested in this trial

  • FISH OIL 500MG OMEGA-3 SOFT GEL MINIS
  • Placebo

Treatment groups

300 Participants
are divided into 2 treatment groups